Alumis Inc. Common Stock
NASDAQ:ALMSBiotechnology
+$0.21 today
- Market cap
- $568.87M
- Beta
- -0.54
- P/E (TTM)
- -12.2
- EPS (TTM)
- -$1.90
Volume 2.01M
Average 1.31M
ALMS Common Stock
The par or stated value of issued common shares, plus paid-in capital where reported together.
Alumis Inc. Common StockNASDAQ: ALMS
Common Stock · Q2 FY2026 · quarter ended Jun 2026
Common stock rises 20.0% from a year ago
Common stock stood at $12K at the end of Q2 FY2026, up 20.0% from a year earlier and up 0.0% from the prior quarter. Over 3 fiscal years it compounded at +108.0% a year.
Context
- Common stock amounted to 0.0% of total assets at the end of Q2 FY2026, unchanged from a year earlier.
- Common stock increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether common stock keeps rising in the next quarterly balance sheet after a +20.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Common Stock history
USD · from the balance sheet
- Latest · FY2025
- 9K USD
- Year-over-year change
- +125.0%
- 3-year CAGR
- +108.0%
| Period | Period end | Common Stock | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9K | +125.0% |
| FY2024 | 2024-12-31 | 4K | +300.0% |
| FY2023 | 2023-12-31 | 1K | +0.0% |
| FY2022 | 2022-12-31 | 1K | — |
Common Stock vs competitors
How ALMS compares with its peers on the latest reported figures
- Peers report in different currencies, so common stock is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +20.0% is the 2nd highest of 9, against a peer median of +0.2%.
- Common stock amounts to 0.0% of total assets for ALMS, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
AGMBAgomAb Therapeutics N.V. American Depositary Shares | Sep 2025 | €223.07M EUR | — | — | 134.7% |
| Mar 2026 | €8.68M EUR | +6.8% | +17.4% | 17.7% | |
| Dec 2025 | $121K USD | +9.0% | +5.9% | 1.1% | |
| Mar 2026 | $60.32K USD | +0.5% | +0.9% | 0.1% | |
| Mar 2026 | $29K USD | -3.3% | -1.2% | 0.0% | |
| Mar 2026 | $25K USD | +127.3% | — | 0.0% | |
| Mar 2026 | $18K USD | +0.0% | -53.1% | 0.0% | |
ALMSAlumis Inc. Common Stock | Jun 2026 | $12K USD | +20.0% | +108.0% | 0.0% |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | $3K USD | +0.0% | — | 0.0% |
| Mar 2026 | $1K USD | +0.0% | +0.0% | 0.0% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding ALMS) | — | +0.2% | +0.5% | 0.0% | |
Competitors are the stored peer set for ALMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Alumis Inc. Common Stock
NASDAQ:ALMS
Intrinsic Alpha fair value
Locked
Current Price
$4.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.